Mutations developing in patients with imatinib-resistant Ph⁺ leukemia treated with second-generation tyrosine kinase inhibitors (TKIs).
 A) New Abl kinase mutations were detected in 61 imatinib-resistant CML patients and the position and frequency of each mutation is outlined in the graph. B) Imatinib-resistant patients (either with or without preexisting Abl kinase mutations received therapy with a second generation TKI (dasatinib, nilotinib, or SKI-606 [bosutinib]) and the subsequent development or loss of mutations are described. A smaller subset went on to receive therapy with a third TKI as indicated. C) The location and frequency of the development or loss of Abl kinase mutations with second/third line TKI therapy are further characterized.⁶³
 This research was originally published in Blood. Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110:4005–4011. © the American Society of Hematology.